Haynes International Announces Network Outage

Written by Customer Service on June 11, 2023. Posted in Public Companies.

KOKOMO, Ind., June 11, 2023 (GLOBE NEWSWIRE) — Haynes International, Inc. (NASDAQ GM: HAYN), a leading developer, manufacturer and marketer of technologically advance high-performance alloys (the “Company”), announced today that yesterday morning the Company began experiencing a network outage indicative of a cybersecurity threat. Upon discovery, the Company engaged third-party specialists to assist in investigating the source of this outage, confirm its impact on the Company’s systems, and to securely restore full functionality to the Company’s systems as soon as possible. The Company’s investigation into this matter is ongoing. Please contact Angela Kohlheim at investor_relations@haynesintl.com with any questions. About Haynes International Haynes International, Inc is a leading developer, manufacturer, and marketer of technologically...

Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

Written by Customer Service on June 11, 2023. Posted in Public Companies.

Extended Phase 1 data reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE) Across all patients (n=10), a single dose of NTLA-2002 led to a 95% mean reduction in monthly HAE attack rate through the latest follow-up All patients who achieved greater than 60% plasma kallikrein reduction (n=9) remain completely attack free following the 16-week primary observation period through the latest follow-up; longest attack-free interval is 13.0 months and ongoing All patients who discontinued concomitant long-term HAE prophylaxis treatment after NTLA-2002 administration (n=6) have reported no HAE attacks since discontinuation through the latest follow-up NTLA-2002 has been well tolerated at all dose levels Intellia to host investor webcast on Monday, June 12, at 8 a.m. ET CAMBRIDGE, Mass.,...

Governor Ned Lamont to Tour MannKind June 12 as It Reaches a Manufacturing Milestone

Written by Customer Service on June 11, 2023. Posted in Public Companies.

DANBURY, Conn., June 11, 2023 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD) will host Connecticut Governor Ned Lamont for a tour of its headquarters on Monday, June 12. The visit coincides with MannKind reaching a manufacturing milestone as it has successfully scaled-up operations for increased production capacity of Tyvaso DPI®. Through MannKind’s partnership with United Therapeutics the current expansion project represents a $60 million investment. Construction is ongoing to build out new manufacturing space designed to expand production in anticipation of the continued growth of Tyvaso DPI. In the past two years, MannKind has experienced more than a 250% increase in its Connecticut workforce across manufacturing, R&D and support functions. DATE/TIMES: MONDAY, JUNE 12, 2023 10:00 a.m. – 11:00 a.m. LOCATION: MannKind 40...

Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress

Written by Customer Service on June 11, 2023. Posted in Public Companies.

– 35% CR rate (7/20) among patients with relapsed/refractory NPM1-mutant AML treated at 600 mg dose (RP2D) – – 33% (2/6) of patients with FLT3 co-mutations and 50% (4/8) of patients with IDH co-mutations achieved a CR on ziftomenib – – Ziftomenib monotherapy drives durable remissions, with median DoR of 8.2 months – – Data suggest ziftomenib is less likely to induce menin resistance mutations – – Enrollment in Phase 2 registration-directed trial in NPM1-mutant AML continues to outperform projections – – First combination study in NPM1-mutant and KMT2A-rearranged AML on track to dose first patients this quarter – – Management to host virtual investor event at 8:00 a.m. ET on Monday, June 12 – SAN DIEGO, June 11, 2023 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing...

M	T	W	T	F	S	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30

Day: June 11, 2023